Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 18/20 | 0.57 |
| ▸ | FFAR4 | Q5NUL3 | 9/20 | 0.51 |
| ▸ | GNA15 | P30679 | 1/20 | 0.48 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CCNC | P24863 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2298891 | 0.90 | FFAR1 (0.60) | FFAR1FFAR4GNA15PTGER3TDP1 | |
| SCHEMBL15006524 | 0.90 | FFAR1 (0.44) | FFAR1FFAR4GNA15PTGER3TDP1 | |
| SCHEMBL2299686 | 0.85 | FFAR1 (0.56) | FFAR1FFAR4 | |
| SCHEMBL2298165 | 0.83 | FFAR1 (0.58) | FFAR1FFAR4 | |
| SCHEMBL2300959 | 0.83 | FFAR1 (0.61) | FFAR1FFAR4 | |
| SCHEMBL2301765 | 0.78 | FFAR1 (0.63) | FFAR1FFAR4GNA15PTGER3TDP1 | |
| SCHEMBL14931957 | 0.78 | PTGES (0.44) | FFAR1FFAR4CCNCCDK8 | |
| SCHEMBL2301629 | 0.75 | FFAR1 (0.58) | FFAR1FFAR4GNA15PTGER3TDP1 | |
| SCHEMBL2300603 | 0.73 | FFAR1 (0.51) | FFAR1FFAR4 | |
| SCHEMBL12427701 | 0.73 | CYP11B2 (0.47) | CCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461183-B2 | PPAR agonist compounds, preparation and uses | GENFIT (FR) | 2013-06-11 | — | — | US | claimed |
| EP-2310371-B1 | PPAR AGONIST COMPOUNDS AND PREPARATION AND USES THEREOF FOR TREATING DIABETES AND/OR DYSLIPIDEMIA | GENFIT (FR) | 2013-05-15 | — | — | EP | claimed |
| US-20110195993-A1 | PPAR AGONIST COMPOUNDS, PREPARATION AND USES | GENFIT (FR) | 2011-08-11 | — | — | US | claimed |
| WO-2016149299-A1 | THERAPEUTIC COMPOUNDS THAT SUPPRESS PROTEIN ARGININE METHYLTRANSFERASE ACTIVITY FOR REDUCING TUMOR CELL PROLIFERATION | EPINOVA THERAPEUTICS CORP. (US) | 2016-09-22 | — | — | WO | disclosed |
| US-20160271149-A1 | THERAPEUTIC COMPOUNDS THAT SUPPRESS PROTEIN ARGININE METHYLTRANSFERASE ACTIVITY FOR REDUCING TUMOR CELL PROLIFERATION | EPINOVA THERAPEUTICS CORP. | 2016-09-22 | — | — | US | disclosed |
| US-8461183-B2 | PPAR agonist compounds, preparation and uses | GENFIT (FR) | 2013-06-11 | — | — | US | disclosed |
| EP-2310371-B1 | PPAR AGONIST COMPOUNDS AND PREPARATION AND USES THEREOF FOR TREATING DIABETES AND/OR DYSLIPIDEMIA | GENFIT (FR) | 2013-05-15 | — | — | EP | disclosed |
| US-20110195993-A1 | PPAR AGONIST COMPOUNDS, PREPARATION AND USES | GENFIT (FR) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195993-A1 | PPAR AGONIST COMPOUNDS, PREPARATION AND USES | PPARD, PPARA, PPARG | FFAR1 10/4885FFAR4 6/4885GNA15 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.